相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma
Prashanthi Dharanipragada et al.
CANCER DISCOVERY (2023)
The KRAS-G12C inhibitor: activity and resistance
Jiao Liu et al.
CANCER GENE THERAPY (2022)
Chk1 dynamics in G2 phase upon replication stress predict daughter cell outcome
Vicente Lebrec et al.
DEVELOPMENTAL CELL (2022)
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition
David Gallo et al.
NATURE (2022)
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells
Moiez Ali et al.
SCIENCE TRANSLATIONAL MEDICINE (2022)
A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells
Mariangela Russo et al.
NATURE GENETICS (2022)
EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada
M. Sara Kuruvilla et al.
LUNG CANCER (2022)
The DNA-damage kinase ATR activates the FANCD2-FANCI clamp by priming it for ubiquitination
Tamara Sijacki et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2022)
Fanconi anemia proteins and genome fragility: unraveling replication defects for cancer therapy
Nibal Badra Fajardo et al.
TRENDS IN CANCER (2022)
Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling
Chen Yang et al.
NATURE COMMUNICATIONS (2021)
Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies
Devon A. Lukow et al.
DEVELOPMENTAL CELL (2021)
Cycling cancer persister cells arise from lineages with distinct programs
Yaara Oren et al.
NATURE (2021)
Replication-dependent histone biosynthesis is coupled to cell-cycle commitment
Claire Armstrong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Hypertranscription and replication stress in cancer
Akhil Bowry et al.
TRENDS IN CANCER (2021)
Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study
Kristof Cuppens et al.
DRUGS-REAL WORLD OUTCOMES (2021)
Beyond Kinases: Targeting Replication Stress Proteins in Cancer Therapy
Katherine E. Baillie et al.
TRENDS IN CANCER (2021)
The Research Progress of Direct KRAS G12C Mutation Inhibitors
Ai Yang et al.
PATHOLOGY & ONCOLOGY RESEARCH (2021)
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Jenny Y. Xue et al.
NATURE (2020)
Temporal integration of mitogen history in mother cells controls proliferation of daughter cells
Mingwei Min et al.
SCIENCE (2020)
Regulation of the error-prone DNA polymerase Polκ by oncogenic signaling and its contribution to drug resistance
Kelsey Temprine et al.
SCIENCE SIGNALING (2020)
ERK2 Phosphorylates PFAS to Mediate Posttranslational Control of De Novo Purine Synthesis
Eunus S. Ali et al.
MOLECULAR CELL (2020)
EllipTrack: A Global-Local Cell-Tracking Pipeline for 2D Fluorescence Time-Lapse Microscopy
Chengzhe Tian et al.
CELL REPORTS (2020)
Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells
Luca Gerosa et al.
CELL SYSTEMS (2020)
Immunofluorescence Staining of Paraffin Sections Step by Step
Sami Zaqout et al.
FRONTIERS IN NEUROANATOMY (2020)
Mutant p53 in Cancer Progression and Targeted Therapies
Gaoyang Zhu et al.
FRONTIERS IN ONCOLOGY (2020)
Replication Licensing Aberrations, Replication Stress, and Genomic Instability
Michalis Petropoulos et al.
TRENDS IN BIOCHEMICAL SCIENCES (2019)
Comprehensive Integration of Single-Cell Data
Tim Stuart et al.
CELL (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Adaptive mutability of colorectal cancers in response to targeted therapies
Mariangela Russo et al.
SCIENCE (2019)
Replication stress induces mitotic death through parallel pathways regulated by WAPL and telomere deprotection
V. Pragathi Masamsetti et al.
NATURE COMMUNICATIONS (2019)
Fanconi anemia proteins counteract the implementation of the oncogene-induced senescence program
Anne Helbling-Leclerc et al.
SCIENTIFIC REPORTS (2019)
Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
Omid Hamid et al.
CANCERS (2019)
Polytherapy and Targeted Cancer Drug Resistance
Nilanjana Chatterjee et al.
TRENDS IN CANCER (2019)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
DNA Replication Determines Timing of Mitosis by Restricting CDK1 and PLK1 Activation
Bennie Lemmens et al.
MOLECULAR CELL (2018)
Replication stress induces accumulation of FANCD2 at central region of large fragile genes
Yusuke Okamoto et al.
NUCLEIC ACIDS RESEARCH (2018)
Stochastic Endogenous Replication Stress Causes ATR-Triggered Fluctuations in CDK2 Activity that Dynamically Adjust Global DNA Synthesis Rates
Leighton H. Daigh et al.
CELL SYSTEMS (2018)
Control of the Restriction Point by Rb and p21
Justin Moser et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study
Julia K. Tietze et al.
Oncotarget (2018)
Ki67 is a Graded Rather than a Binary Marker of Proliferation versus Quiescence
Iain Miller et al.
CELL REPORTS (2018)
Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
Naiara Santana-Codina et al.
NATURE COMMUNICATIONS (2018)
Translesion polymerase kappa-dependent DNA synthesis underlies replication fork recovery
Peter Tonzi et al.
ELIFE (2018)
Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state
Mohammad Fallahi-Sichani et al.
MOLECULAR SYSTEMS BIOLOGY (2017)
Current Development Status of MEK Inhibitors
Ying Cheng et al.
MOLECULES (2017)
Rare cell variability and drug- induced reprogramming as a mode of cancer drug resistance
Sydney M. Shaffer et al.
NATURE (2017)
The essential kinase ATR: ensuring faithful duplication of a challenging genome
Joshua C. Saldivar et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
The identification of FANCD2 DNA binding domains reveals nuclear localization sequences
Joshi Niraj et al.
NUCLEIC ACIDS RESEARCH (2017)
Endogenous Replication Stress in Mother Cells Leads to Quiescence of Daughter Cells
Mansi Arora et al.
CELL REPORTS (2017)
Linear Integration of ERK Activity Predominates over Persistence Detection in Fra-1 Regulation
Taryn E. Gillies et al.
CELL SYSTEMS (2017)
Irreversible APCCdh1 Inactivation Underlies the Point of No Return for Cell-Cycle Entry
Steven D. Cappell et al.
CELL (2016)
FANCD2 Facilitates Replication through Common Fragile Sites
Advaitha Madireddy et al.
MOLECULAR CELL (2016)
RAD52 Facilitates Mitotic DNA Synthesis Following Replication Stress
Rahul Bhowmick et al.
MOLECULAR CELL (2016)
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
Aaron N. Hata et al.
NATURE MEDICINE (2016)
Toward a Shared Vision for Cancer Genomic Data
Robert L. Grossman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Michael Ramirez et al.
NATURE COMMUNICATIONS (2016)
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Yue-Lun Zhang et al.
Oncotarget (2016)
FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair
Zeina Kais et al.
CELL REPORTS (2016)
FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells
Julie Bourseguin et al.
SCIENTIFIC REPORTS (2016)
DNA damage and the balance between survival and death in cancer biology
Wynand P. Roos et al.
NATURE REVIEWS CANCER (2016)
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway
Andrew F. Voter et al.
JOURNAL OF BIOMOLECULAR SCREENING (2016)
Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer
T. T. Seppala et al.
BRITISH JOURNAL OF CANCER (2015)
ATR-Mediated Phosphorylation of FANCI Regulates Dormant Origin Firing in Response to Replication Stress
Yu-Hung Chen et al.
MOLECULAR CELL (2015)
Replication stress activates DNA repair synthesis in mitosis
Sheroy Minocherhomji et al.
NATURE (2015)
Targeting RAS-ERK signalling in cancer: promises and challenges
Ahmed A. Samatar et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
The Proliferation-Quiescence Decision Is Controlled by a Bifurcation in CDK2 Activity at Mitotic Exit
Sabrina L. Spencer et al.
CELL (2013)
FANCD2 Binds MCM Proteins and Controls Replisome Function upon Activation of S Phase Checkpoint Signaling
Gerald Lossaint et al.
MOLECULAR CELL (2013)
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors
Tara R. Rheault et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito et al.
CANCER CELL (2012)
DNA damage bypass operates in the S and G2 phases of the cell cycle and exhibits differential mutagenicity
Noam Diamant et al.
NUCLEIC ACIDS RESEARCH (2012)
Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
Dalia Ercan et al.
CANCER DISCOVERY (2012)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Examination of the expanding pathways for the regulation of p21 expression and activity
Yong-Sam Jung et al.
CELLULAR SIGNALLING (2010)
γH2AX: a sensitive molecular marker of DNA damage and repair
L-J Mah et al.
LEUKEMIA (2010)
Cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
Jenn-Yu Wu et al.
CLINICAL CANCER RESEARCH (2008)
The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition
S. Meloche et al.
ONCOGENE (2007)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)